Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.
about
A subnanomolar fluorescent probe for protein kinase CK2 interaction studiesPotent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided HybridizationStructure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in VivoA Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian CancerIdentification of novel CK2 inhibitors with a benzofuran scaffold by novel non-radiometric in vitro assays.Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.Antitumoral activity of allosteric inhibitors of protein kinase CK2.Therapeutic CK2 inhibition attenuates diverse prosurvival signaling cascades and decreases cell viability in human breast cancer cells.Casein Kinase 2: a novel player in glioblastoma therapy and cancer stem cells.Inhibition of CK2α down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cellsThe casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.Dysregulation of RNA polymerase I transcription during disease.MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.The protein kinase 2 inhibitor tetrabromobenzotriazole protects against renal ischemia reperfusion injury.Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer's disease pathology.Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-cateninIn Search of Small Molecule Inhibitors Targeting the Flexible CK2 Subunit Interface.Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.CK2 Molecular Targeting-Tumor Cell-Specific Delivery of RNAi in Various Models of Cancer.Casein kinase: the triple meaning of a misnomer.The protein kinase 2 inhibitor CX-4945 regulates osteoclast and osteoblast differentiation in vitro.Novel investigational therapies for treating biliary tract carcinoma.Specific inhibition of CK2α from an anchor outside the active siteDifferent Persistence of the Cellular Effects Promoted by Protein Kinase CK2 Inhibitors CX-4945 and TDB.Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.CK2α, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells.Novel polycarbo-substituted alkyl (thieno[3,2-c]quinoline)-2-carboxylates: synthesis and cytotoxicity studies.Regulation of cellular proliferation in acute lymphoblastic leukemia by Casein Kinase II (CK2) and Ikaros.Potent and Selective CK2 Kinase Inhibitors with Effects on Wnt Pathway Signaling in Vivo.Structural determinants of CX-4945 derivatives as protein kinase CK2 inhibitors: a computational studyApproved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.Inhibition of CK2α down-regulates Notch1 signalling in lung cancer cells.Exploring the prominent performance of CX-4945 derivatives as protein kinase CK2 inhibitors by a combined computational study.Design and synthesis of a novel class of CK2 inhibitors: application of copper- and gold-catalysed cascade reactions for fused nitrogen heterocycles.Molecular characterization of clear cell renal cell carcinoma identifies CSNK2A1, SPP1 and DEFB1 as promising novel prognostic markers.Exploring the Pivotal Role of the CK2 Hinge Region Sub-Pocket in Binding with Tricyclic Quinolone Analogues by Computational Analysis.Site-Specific Labeling of Protein Kinase CK2: Combining Surface Display and Click Chemistry for Drug Discovery Applications.CK2 is a key regulator of SLC4A2-mediated Cl-/HCO3- exchange in human airway epithelia.Generation and quantitative proteomics analysis of CK2α/α'(-/-) cells.
P2860
Q27682639-88F8A1AE-C887-4D82-9576-768C8F2C4721Q27684133-EA3B83FD-34B5-4923-AE7F-34A1C73E2D74Q27684208-C227AE32-6BDE-4791-BB92-D8F17085172FQ28551341-126F8DB0-649F-4EAD-8D63-EE91A867B549Q33959504-5BEFE143-E118-45F6-B6A8-0818A9E68A70Q33960547-E6B6C392-B042-4A33-BAC5-A328CA8F9AD1Q34106499-7D2BD2A3-485F-421C-B525-FE061A516098Q34227776-6A6A52D9-C39F-4CC1-A929-4D6DDFCC956BQ34247901-E105FCA1-8CEB-4F1B-A74E-8F685DE70700Q34328051-5976CBBC-7214-4C28-9818-8C00ADB735D9Q34471660-ECA1188F-4ABB-47E7-8BA1-A40D9D8AB47BQ34645436-61A99253-4266-45A0-B464-080F0065F455Q35197507-E10899D9-78E7-4A31-9248-D9C28477E2F3Q36109789-7C0C58B8-7EEC-4A8D-AB49-FE698A3F8F9AQ36433202-36D0AF20-9A8A-460A-A883-C9A0BF3713B5Q37599312-1A0F1DAB-B06B-48C4-94D4-87155E8203FEQ37619722-9F150455-D806-43AA-9FC3-965371FDD7C7Q37731316-E9060D05-51DC-4272-88D2-45A9A5047A9FQ37731326-53563D47-9F97-43A8-927A-F3D402FA06B2Q37731329-B855E2B8-F458-4264-84B5-3E15A0FBF159Q38211598-F5380401-A834-4085-9168-88592C39F930Q38443998-5F8A6E73-9624-4E0D-8977-EBAD57A08DD5Q38799963-C663F042-348D-4EF8-BAFD-A28AFF8DF878Q38815725-48752045-C1C1-4B16-86C8-9CF2C80C3438Q38820266-643A0091-3010-4643-9164-5F658EFE09F0Q38897744-2C152753-48CB-4DE7-8CB2-DC485B48723BQ38937997-C241B9E8-E123-4C36-8302-FF211BE3F5AFQ38940077-1761C7F2-6B47-493C-ABDD-340AA08B0F3DQ38964075-D68E8DD4-6B65-4577-B599-CA0AA5147318Q38966094-378479D3-A0C8-4C60-A2D8-74EBD68ECC54Q38988071-42185226-3F03-4C3E-8B17-920D05276198Q38989374-3A7F21A4-7B78-43C8-A63E-A0EC64CD56AAQ39155162-655FCA1C-99B4-43AE-92DB-E29AC692FB03Q39227396-5CBD364F-9E33-4B74-A51F-778B5A118171Q39345587-25E76E4C-2FBB-4212-B412-E537C68F9F77Q39997736-DE16A673-E2E6-4BAC-A800-4ECBD538F74EQ40189553-D9D83BC1-482A-408C-82A5-0B2BA068F8EEQ41202024-CAC000BA-ADF0-480B-B467-29F7215B6F09Q41368424-2B42AB02-5DDB-48DE-A057-423F8934F93FQ41835528-A9B5C838-1DF9-4B81-B325-F1F9D5D53D49
P2860
Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Discovery and SAR of 5-(3-chlo ...... 2 for the treatment of cancer.
@ast
Discovery and SAR of 5-(3-chlo ...... 2 for the treatment of cancer.
@en
Discovery and SAR of 5-(3-chlo ...... 2 for the treatment of cancer.
@nl
type
label
Discovery and SAR of 5-(3-chlo ...... 2 for the treatment of cancer.
@ast
Discovery and SAR of 5-(3-chlo ...... 2 for the treatment of cancer.
@en
Discovery and SAR of 5-(3-chlo ...... 2 for the treatment of cancer.
@nl
prefLabel
Discovery and SAR of 5-(3-chlo ...... 2 for the treatment of cancer.
@ast
Discovery and SAR of 5-(3-chlo ...... 2 for the treatment of cancer.
@en
Discovery and SAR of 5-(3-chlo ...... 2 for the treatment of cancer.
@nl
P2093
P356
P1476
Discovery and SAR of 5-(3-chlo ...... 2 for the treatment of cancer.
@en
P2093
Adam Siddiqui-Jain
Anne Vialettes
Caroline Ho
Chris Proffitt
David M Ryckman
Denis Drygin
Eric Stefan
Fabrice Pierre
Jeffrey P Whitten
Jerome Michaux
P304
P356
10.1021/JM101251Q
P407
P577
2010-12-21T00:00:00Z